Forte Biosciences (FBRX) Fundamental Analysis: Revenue, Earnings & Valuation

8.56 / 10

Outperform

Fundamentals score 8.6/10, rated Outperform. Key strengths are Profit‑MV and Cash‑UP, while Current assets turnover and high inventory days drag performance. Weighted factor analysis highlights Asset‑MV and Cash‑UP as primary drivers, supporting a robust valuation.

Analysis Checks(7/10)

Profit-MV

Value0.41

Score2/3

Weight1.42%

1M Return0.17%

Net income-Revenue

Value-0.16

Score2/3

Weight-1.83%

1M Return-0.22%

PB-ROE

Value-0.05

Score1/3

Weight-1.72%

1M Return-0.23%

Current assets turnover ratio

Value1.78

Score1/3

Weight-2.29%

1M Return-0.27%

Cash-UP

Value-0.01

Score3/3

Weight25.75%

1M Return2.87%

Total assets turnover ratio

Value0.58

Score2/3

Weight12.33%

1M Return1.43%

Cost of sales ratio (%)

Value70.30

Score3/3

Weight15.69%

1M Return1.95%

Asset-MV

Value-0.48

Score3/3

Weight64.56%

1M Return6.94%

Inventory turnover days

Value230.09

Score1/3

Weight-20.03%

1M Return-2.65%

Cash-MV

Value-0.09

Score2/3

Weight6.13%

1M Return0.79%

Is FBRX undervalued or overvalued?

FBRX scores 8.56/10 on fundamentals and holds a Discounted valuation at present. Backed by its -65.29% ROE, 0.00% net margin, -7.97 P/E ratio, 4.02 P/B ratio, and 99.51% earnings growth, these metrics solidify its Outperform investment rating.